Renal impairment is associated with coronary heart disease in HIV-positive men

HIV Clinical Trials

Volumn 13, Issue 6, 2012, Pages 343-349

  Campbell, Lucy ^a   Desai, Mitesh ^b   Hegazi, Aseel ^c   Ibrahim, Fowzia ^a   Melikian, Narbeh ^d   Hay, Phillip ^c   Fox, Julie ^b   Post, Frank ^a,d  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c ST GEORGE S HOSPITAL   (United Kingdom)

^d KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

abacavir; cardiovascular; coronary; HIV; infarction; kidney

Indexed keywords

ABACAVIR; CREATININE; HEPATITIS B SURFACE ANTIBODY; HEPATITIS C ANTIBODY; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TROPONIN; VIRUS RNA;

ADULT; AGING; ARTICLE; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY BYPASS SURGERY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DRUG USE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INCIDENCE; INFECTION RISK; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; TRANSLUMINAL CORONARY ANGIOPLASTY;

ADULT; CORONARY ARTERY DISEASE; GLOMERULAR FILTRATION RATE; HIV SEROPOSITIVITY; HUMANS; MALE; MIDDLE AGED; RENAL INSUFFICIENCY; RISK FACTORS;

EID: 84870609435     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/hct1306-343     Document Type: Article

References (42)

1. Currier JS, Lundgren JD, Carr A, et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation. 2008;118(2):e29-35
2. Klein D, Hurley LB, Quesenberry CP Jr, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection ? J Acquir Immune Defi c Syndr. 2002;30(5):471-477
3. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metabol. 2007;92(7): 2506-2512 (Pubitemid 47037350)
4. Currier JS, Taylor A, Boyd F, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defi c Syndr. 2003;33(4):506-512 (Pubitemid 36886080)
5. Aberg JA. Cardiovascular complications in HIV management: past, present, and future. J Acquir Immune Defi c Syndr. 2009;50(1):54-64
6. Calza L, Manfredi R, Verucchi G. Myocardial infarction risk in HIV-infected patients: epidemiology, pathogenesis, and clinical management. AIDS. 2010;24(6):789-802
7. Neuhaus J, Jacobs DR Jr, Baker JV, et al. Markers of infl ammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis. 2010;201(12): 1788-1795
8. Kaplan RC, Sinclair E, Landay AL, et al. T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis. 2011;203(4):452-463
9. Solages A, Vita JA, Thornton DJ, et al. Endothelial function in HIV-infected persons. Clin Infect Dis. 2006;42(9): 1325-1332
10. Grunfeld C, Delaney JA, Wanke C, et al. Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS. 2009;23(14):1841-1849
11. Hsue PY, Hunt PW, Schnell A, et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIVassociated atherosclerosis. AIDS. 2009;23(9):1059-1067
12. Kingsley LA, Cuervo-Rojas J, Munoz A, et al. Subclinical coronary atherosclerosis, HIV infection and antiretroviral therapy: Multicenter AIDS Cohort Study. AIDS. 2008;22(13):1589-1599
13. Lo J, Abbara S, Shturman L, Soni A, et al. Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS. 2010;24(2):243-253
14. Baker JV, Neuhaus J, Duprez D, et al. Changes in infl ammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. J Acquir Immune Defi c Syndr. 2011;56(1):36-43
15. Calmy A, Gayet-Ageron A, Montecucco F, et al. HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS. 2009;23(8):929-939
16. Baker JV, Henry WK, Patel P, et al. Progression of carotid intima-media thickness in a contemporary human immunodeficiency virus cohort. Clin Infect Dis. 2011;53(8):826-835
17. Ho JE, Deeks SG, Hecht FM, et al. Initiation of antiretroviral therapy at higher nadir CD4+ T-cell counts is associated with reduced arterial stiffness in HIV-infected individuals. AIDS. 2010;24(12):1897-1905
18. Torriani FJ, Komarow L, Parker RA, et al. Endothelial function in human immunodefi ciency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: the ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol. 2008;52(7):569-576
19. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ countguided interruption of antiretroviral treatment. N Engl J Med. 2006;355(22):2283-2296 (Pubitemid 44837777)
20. Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356(17):1723-1735 (Pubitemid 46658704)
21. Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008;371(9622):1417-1426
22. Post FA, Holt SG. Recent developments in HIV and the kidney. Curr Opin Infect Dis. 2009;22(1):43-48
23. Choi AI, Li Y, Deeks SG, Grunfeld C, Volberding PA, Shlipak MG. Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. Circulation. 2010;121(5):651-658
24. Serrano-Villar S, Estrada V, Gomez-Garre D, et al. Incipient renal impairment as a predictor of subclinical atherosclerosis in HIV-infected patients. J Acquir Immune Defi c Syndr. 2012;59(2):141-148
25. Jotwani V, Scherzer R, Choi A, et al. Reduced kidney function and preclinical atherosclerosis in HIV-infected individuals: the study of fat redistribution and metabolic change in HIV infection (FRAM). Am J Nephrol. 2011;33(5):453-460
26. George E, Lucas GM, Nadkarni GN, Fine DM, Moore R, Atta MG. Kidney function and the risk of cardiovascular events in HIV-1-infected patients. AIDS. 2010;24(3):387-394
27. Lifson AR, Belloso WH, Davey RT, et al. Development of diagnostic criteria for serious non-AIDS events in HIV clinical trials. HIV Clin Trials. 2010;11(4):205-219
28. Ibrahim F, Hamzah L, Jones R, Nitsch D, Sabin C, Post FA. Comparison of CKD-EPI and MDRD to estimate baseline renal function in HIV-positive patients. Nephrol Dial Transplant. 2011;27(6):2291-2297
29. Aboud M, Elgalib A, Pomeroy L, Panayiotakopoulos G, et al. Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for clinical management: the CREATE 1 study. Int J Clin Pract. 2010;64(9):1252-1259
30. Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073-2081
31. Ibrahim F, Naftalin C, Cheserem E, et al. Immunodefi ciency and renal impairment are risk factors for HIV-associated acute renal failure. AIDS. 2010;24(14):2239-2244
32. Campbell LJ, Ibrahim F, Fisher M, Holt SG, Hendry BM, Post FA. Spectrum of chronic kidney disease in HIV-infected patients. HIV Med. 2009;10(6):329-336
33. Himmelfarb J, Ikizler TA. Hemodialysis. N Engl J Med. 2010;363(19):1833-1845
34. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS. 2008;22(14):F17-24
35. Choi AI, Vittinghoff E, Deeks SG, Weekley CC, Li Y, Shlipak MG. Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons. AIDS. 2011;25(10):1289-1298
36. Lang S, Mary-Krause M, Cotte L, et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med. 2010;170(14):1228-1238
37. Lichtenstein KA, Armon C, Buchacz K, et al. Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clin Infect Dis. 2010;51(4):435-447
38. Triant VA, Regan S, Lee H, Sax PE, Meigs JB, Grinspoon SK. Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system. J Acquir Immune Defi c Syndr. 2010;55:615-619
39. Bedimo RJ, Westfall AO, Drechsler H, Vidiella G, Tebas P. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. Clin Infect Dis. 2011;53(1):84-91
40. Cruciani M, Zanichelli V, Serpelloni G, et al. Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data. AIDS. 2011;25(16): 1993-2004
41. Post FA, Campbell LJ. Abacavir and increased risk of myocardial infarction. Lancet. 2008;372(9641):803; author reply 4-5
42. Hasse B, Ledergerber B, Furrer H, et al. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis. 2011;53(11):1130-1139.